Ling-Hui Zeng
Pharmacologist who studies mTOR signalling in epilepsy; as a researcher in Michael Wong's group she was first author of the mouse study showing that rapamycin prevents epilepsy in a tuberous sclerosis model.
School of Medicine, Hangzhou City University (formerly Zhejiang University City College), Hangzhou · earlier Department of Neurology, Washington University School of Medicine, St. Louis (about 2007–2008, with Michael Wong)
Lab lineagetrained under Michael Wong →
Ling-Hui Zeng was first author of the 2008 Annals of Neurology study from Michael Wong's group (ZEN2008). Mice lacking Tsc1 mainly in glial cells develop progressive epilepsy and die early. Rapamycin started at postnatal day 14 prevented the epilepsy and early death, and rapamycin started at 6 weeks, after seizures had begun, suppressed seizures and prolonged survival. It also reversed raised phospho-S6, astrogliosis and neuronal disorganisation. The results are from a mouse model, not patients, and they are part of the background to the later EXIST-3 trial (FRE2016).
Zeng worked in the Department of Neurology at Washington University in St. Louis in the mid-2000s, on the same Tsc1 glial knockout mouse. She then moved to Hangzhou, to Zhejiang University City College, now Hangzhou City University, where her group has continued to publish on mTOR in seizures, including rat studies on the timing and dose of rapamycin, and more recently on other neural and tumour signalling pathways.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2008 | A | Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex ZEN2008 First author: in Tsc1 glial knockout mice, early rapamycin prevents epilepsy and early death, and late rapamycin suppresses established seizures. |
Co-authors in the Atlas
People with a profile here who share at least one study with Ling-Hui Zeng.
- Michael Wong Pediatric epileptologist whose lab studies how epilepsy develops, with a focus on mTOR in tuberous sclerosis complex and brain injury; senior author of the mouse study in which rapamycin prevented epilepsy in a TSC model.
Every researcher with a profile →
Thank you. Your answer was counted anonymously.
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.